{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:47:27Z","timestamp":1790153247478,"version":"4.0.1"},"reference-count":52,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,10,15]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Systemic sclerosis (SSc) is a rare autoimmune disease currently classified into two subgroups based on skin extension. The aim of this study was to determine in a large cohort whether the determination of autoantibody (AAb) profile among a full antinuclear AAbs panel including nine specificities had a higher impact than skin phenotype on stratifying the risk of organ involvement and mortality in SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data for patients with SSc followed in seven French university hospitals were retrospectively analysed in terms of skin phenotype, AAbs (anti-topoisomerase I (ATA), anticentromere (ACA), anti-RNA polymerase III (anti-RNAPIII), anti-U1RNP, anti-U3RNP, anti-Pm\/Scl, anti-Ku, anti-Th\/To, anti-NOR90), organ involvement and mortality. Multivariate analyses were performed to identify independent factors associated with organ involvement and mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 1605 patients with SSc (367 with diffuse cutaneous SSc). On multivariate analysis, ATAs were associated with interstitial lung disease and mortality (OR=3.27 (95% CI 2.42 to 4.42); HR=1.9 (95% CI 1.01 to 3.58)), anti-RNAPIII with scleroderma renal crisis and mortality (OR=7.05 (95% CI 2.98 to 16.72); HR=2.35 (95% CI 1.12 to 4.93)), anti-U1RNP with arthritis (OR=3.79 (95% CI 2.16 to 6.67)), anti-Pm\/Scl and anti-Ku with myositis (OR=7.09 (95% CI 3.87 to 12.98) and 7.99 (95% CI 2.41 to 26.46)). The skin phenotype was not associated with survival or organ involvement on multivariate analysis without stepwise selection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study unravels, by contrast with skin phenotype, a strong association between AAbs specificities, organ involvement and outcome in SSc and suggests that patients\u2019 classification based on only skin extension is not sufficient for defining prognosis and phenotype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004580","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T01:25:46Z","timestamp":1732152346000},"page":"e004580","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-9146","authenticated-orcid":false,"given":"Kevin","family":"Didier","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, University Hospital Centre Reims, Reims, Grand Est, France"},{"name":"UR7509 - IRMAIC, University of Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-2441","authenticated-orcid":false,"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[{"name":"Univ. Lille, U1286 \u2013 Infinite \u2013 Institute for Translational Research in Inflammation, Lille, France"},{"name":"Institut Universitaire de France, Paris, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-0380","authenticated-orcid":false,"given":"Ailsa","family":"Robbins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, University Hospital Centre Reims, Reims, Grand Est, France"},{"name":"UR7509 - IRMAIC, University of Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-0180","authenticated-orcid":false,"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"Rheumatology Department, FHU ACRONIM, University Hospital Centre Bordeaux, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-8534","authenticated-orcid":false,"given":"Thomas","family":"Barnetche","sequence":"additional","affiliation":[{"name":"Rheumatology Department, FHU ACRONIM, University Hospital Centre Bordeaux, Bordeaux, Nouvelle-Aquitaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4652-2907","authenticated-orcid":false,"given":"C\u00e9cile","family":"Contin-Bordes","sequence":"additional","affiliation":[{"name":"CIRID, UMR CNRS-5164, ImmunoConcEpT, Bordeaux University, Bordeaux, France"},{"name":"Immunology and Immunogenetic Department, CHU Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Hot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, CHU Edouard Herriot, Hospices Civils de Lyon, University Hospital Centre Lyon, Lyon, Auvergne-Rh\u00f4ne-Alpes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Fort","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, CHU Edouard Herriot, Hospices Civils de Lyon, University Hospital Centre Lyon, Lyon, Auvergne-Rh\u00f4ne-Alpes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Guilpain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Multiorganic Diseases, Local Referral Center for Auto-immune Diseases, Saint-Eloi Hospital, University Hospital Centre of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Maria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Multiorganic Diseases, Local Referral Center for Auto-immune Diseases, Saint-Eloi Hospital, University Hospital Centre of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Agard","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Centre Nantes, Nantes, Pays de la Loire, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Loup","family":"Pennaforte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Centre Reims, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuelle","family":"Viguier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Centre Reims, Reims, Grand Est, France"},{"name":"UR7509 - IRMAIC, University of Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospitals, Strasbourg, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Jolly","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Department, University Hospital Centre Reims, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Barbe","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Giusti","sequence":"additional","affiliation":[{"name":"Immunology laboratory Department, University Hospital Centre Reims, Reims, Grand Est, France"},{"name":"UR7509 - IRMAIC, University of Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[{"name":"Univ. Lille, U1286 \u2013 Infinite \u2013 Institute for Translational Research in Inflammation, Lille, France"},{"name":"D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Servettaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, University Hospital Centre Reims, Reims, Grand Est, France"},{"name":"UR7509 - IRMAIC, University of Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025090312593302000_10.4.e004580.1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.revmed.2019.05.016","article-title":"Updates in systemic sclerosis pathogenesis: Toward new therapeutic opportunities","volume":"40","author":"Didier","year":"2019","journal-title":"Rev Med Interne"},{"key":"2025090312593302000_10.4.e004580.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312593302000_10.4.e004580.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2025090312593302000_10.4.e004580.4","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090312593302000_10.4.e004580.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062901"},{"key":"2025090312593302000_10.4.e004580.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200742"},{"key":"2025090312593302000_10.4.e004580.7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5301\/jsrd.5000256","article-title":"What have multicentre registries across the world taught us about the disease features of systemic sclerosis?","volume":"2","author":"Proudman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2025090312593302000_10.4.e004580.8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312593302000_10.4.e004580.9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5301\/jsrd.5000212","article-title":"Subsets in systemic sclerosis: one size does not fit all","volume":"1","author":"Leclair","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2025090312593302000_10.4.e004580.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"2025090312593302000_10.4.e004580.11","first-page":"96","article-title":"Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study","volume":"31","author":"Heijnen","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312593302000_10.4.e004580.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?","volume":"9","author":"Didier","year":"2018","journal-title":"Front Immunol"},{"key":"2025090312593302000_10.4.e004580.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.005"},{"key":"2025090312593302000_10.4.e004580.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.41153"},{"key":"2025090312593302000_10.4.e004580.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2025090312593302000_10.4.e004580.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"key":"2025090312593302000_10.4.e004580.17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/2397198318783930","article-title":"Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives","volume":"3","author":"Hamaguchi","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"2025090312593302000_10.4.e004580.18","doi-asserted-by":"crossref","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090312593302000_10.4.e004580.19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semarthrit.2020.10.009","article-title":"Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments","volume":"51","author":"Scherlinger","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312593302000_10.4.e004580.20","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/rheumatology\/ket213","article-title":"Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors","volume":"52","author":"Derrett-Smith","year":"2013","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312593302000_10.4.e004580.21","doi-asserted-by":"crossref","first-page":"102842","DOI":"10.1016\/j.autrev.2021.102842","article-title":"Primary biliary cholangitis and systemic sclerosis (Reynolds syndrome): A case-control study","volume":"20","author":"David","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025090312593302000_10.4.e004580.22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312593302000_10.4.e004580.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.029"},{"key":"2025090312593302000_10.4.e004580.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.04.007"},{"key":"2025090312593302000_10.4.e004580.25","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","article-title":"Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - A review","volume":"17","author":"Nunes","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025090312593302000_10.4.e004580.26","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"2025090312593302000_10.4.e004580.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.24409"},{"key":"2025090312593302000_10.4.e004580.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214439"},{"key":"2025090312593302000_10.4.e004580.29","first-page":"1","article-title":"Long-Term Survival and Follow-up of Anti-Th\/to Antibody Positive Systemic Sclerosis Patients","volume":"69","author":"Charlton","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025090312593302000_10.4.e004580.30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02591-2020","article-title":"Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort","volume":"57","author":"Bauer","year":"2021","journal-title":"Eur Respir J"},{"key":"2025090312593302000_10.4.e004580.31","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/art.40534","article-title":"CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis","volume":"70","author":"Hoffmann\u2010Vold","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312593302000_10.4.e004580.32","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of Pulmonary Complications and Long\u2010Term Survival in Systemic Sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312593302000_10.4.e004580.33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/keu450","article-title":"Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population","volume":"54","author":"Hachulla","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312593302000_10.4.e004580.34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early Mortality in a Multinational Systemic Sclerosis Inception Cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312593302000_10.4.e004580.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171443"},{"key":"2025090312593302000_10.4.e004580.36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","article-title":"Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort","volume":"17","author":"Panopoulos","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025090312593302000_10.4.e004580.37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2397198319869564","article-title":"Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis","volume":"5","author":"van den Hombergh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2025090312593302000_10.4.e004580.38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00296-017-3846-7","article-title":"Causes of death, survival and risk factors of mortality in Thai patients with early systemic sclerosis: inception cohort study","volume":"37","author":"Wangkaew","year":"2017","journal-title":"Rheumatol Int"},{"key":"2025090312593302000_10.4.e004580.39","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10067-013-2289-0","article-title":"Mortality in systemic sclerosis-a single centre study from the UK","volume":"32","author":"Strickland","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2025090312593302000_10.4.e004580.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370111"},{"key":"2025090312593302000_10.4.e004580.41","first-page":"109","article-title":"To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?","volume":"36 Suppl 113","author":"Boonstra","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312593302000_10.4.e004580.42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930970","article-title":"Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?","volume":"13","author":"Chepy","year":"2022","journal-title":"Front Immunol"},{"key":"2025090312593302000_10.4.e004580.43","first-page":"491","article-title":"Comparison of two extractable nuclear antigen testing algorithms: ALBIA versus ELISA\/line immunoassay","volume":"48","author":"Chandratilleke","year":"2016","journal-title":"Pathology (Phila)"},{"key":"2025090312593302000_10.4.e004580.44","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2015.1077461"},{"key":"2025090312593302000_10.4.e004580.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.06.041"},{"key":"2025090312593302000_10.4.e004580.46","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1398.030"},{"key":"2025090312593302000_10.4.e004580.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2005.03.042"},{"key":"2025090312593302000_10.4.e004580.48","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.autrev.2017.12.008","article-title":"Antinuclear antibodies: Is the indirect immunofluorescence still the gold standard or should be replaced by solid phase assays?","volume":"17","author":"P\u00e9rez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025090312593302000_10.4.e004580.49","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2021.1907842"},{"key":"2025090312593302000_10.4.e004580.50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/kez374","article-title":"Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study","volume":"59","author":"Sulli","year":"2020","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312593302000_10.4.e004580.51","first-page":"2423","article-title":"Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study","volume":"34","author":"Hachulla","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312593302000_10.4.e004580.52","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180042"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:59:41Z","timestamp":1756929581000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/rmdopen-2024-004580"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004580","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}